Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Evaluating Patients' Experiences Towards Their Immunosuppressive Treatment: A Way to Improve Adherence.
C. Villeneuve,^1,2 M. Grau,¹ M. Essig,^2,3 S. Hegarat,³ J. Zoughbi,³ P. Marquet,^1,2 C. Monchaud.^1,2
¹Service of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France; ²INSERM UMR850, INSERM, Limoges, France; ³Service of Nephrology, Dialysis and Transplantation, CHU Limoges, Limoges, France
In transplantation, low therapeutic adherence is associated with an increased risk of rejection, chronic allograft dysfunction and graft loss. Improving adherence necessitates identifying its barriers,…
2017 American Transplant Congress
Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.
O. Marion,¹ A. Del Bello,¹ I. Ferrandiz,¹ L. Esposito,¹ N. Congy,² A.-L. Hebral,¹ N. Kamar.¹
¹Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; ²Laboratory of Histocompatibility, CHU Rangueil, Toulouse, France
The need for using induction therapy in de novo non-HLA sensitized kidney-transplant patients receiving tacrolimus-based therapy is a matter of debate. The aims of this…
2017 American Transplant Congress
A Nationwide Global Strategy for Kidney Transplantation with Controlled Cardiac Death Donor (cDCD) Has Improved Global Results. Spanish Multicentre SENTRA-GEODAS Group.
J. Portoles,^1,2 M. Perez-Saez,^2,3 D. Janeiro,^1,2 E. Melilli,² N. Maruri Kareaga,² E. de Souza,² F. Llamas,² J. Espi,² P. Martin Moreno,² D. Navarro,² A. Sancho-Calabuig,² M. Rodriguez-Ferrero,² D. Hernandez,² J. Pascual.^2,3
¹Nephrology, Hospital Puerta de Hierro, Majadahonda, Spain; ²GEODAS-SENTRA Public Health Research Net RedinRen16/009/009 RETYC ISCIII, Madrid, Spain; ³Nephrology, Hospital del Mar, Barcelona, Spain
Background: Controlled donation after cardiac death (cDCD) programs are running in US for years and some European countries has recently started on it. National transplant…
2017 American Transplant Congress
Patient-Reported Barriers to the Pre-Kidney Transplant Evaluation in an At-Risk Population in the United States.
M. Lockwood,¹ W. Chon,² M. Josephson,² Y. Becker,² M. Saunders.²
¹College of Nursing, University of Illinois at Chicago, Chicago, IL; ²University of Chicago Medicine, Chicago, IL
Background: Despite our knowledge of barriers to the early stages of the transplant process, we have limited insight into patient reported barriers to the pre-kidney…
2017 American Transplant Congress
Can We Successfully Overcome Obesity as a Barrier for Kidney Transplantation?
K. Zorbas,¹ S. Karhadkar,¹ S. Rao,² K. Lau,¹ I. Lee,² A. Gillespie,² S. Constantinescu,² A. Karachristos,¹ A. Di Carlo.¹
¹Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA; ²Nephrology, Temple University, Philadelphia, PA
Obesity is a significant barrier for kidney transplantation (KT) with higher rates of denial for listing and longer listing to transplantation interval. We examined the…
2017 American Transplant Congress
Impact of Pancreas Transplant Failure in Quality of Life in Simultaneous Kidney Pancreas Transplantation.
B. Alharbi, S. Aquil, H. Sharma, O. Ali, P. Luke, A. Sener.
Departments of Surgery and Microbiology and Immunology, Matthew Mailing Center for Translational Transplant Studies, Western University, London, London, ON, Canada
BackgroundBoth kidney and pancreas transplantation have been shown to be associated with improved quality of life (QoL). In fact, one of the most important outcomes…
2017 American Transplant Congress
Benefits of Multimodal Enhanced Recovery Pathway in Patients Undergoing Kidney Transplantation.
K. Espino,¹ L. Kayler.²
¹Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY; ²Department of Surgery, Erie County Medical Center, Buffalo, NY
Background: Use of Enhanced Recovery After Surgery (ERAS) pathways have been shown to improve patient recovery in several surgical specialties; however, its' effectiveness in kidney…
2017 American Transplant Congress
Lymphoproliferative Disorders After Renal Transplantation Along Two Decades: A Large Longitudinal Study.
A. Franco,¹ D. Hernandez,² N. Maruri,³ A. Alonso,⁴ M. Crespo,⁵ A. Mazuecos,⁶ C. Diaz-Corte,⁷ M. Gentil.⁸
¹Nephrology, Hospital General, Alicante, Spain; ²Nephrology, Hospital Carlos Haya, Málaga, Spain; ³Nephrology, Hospital Cruces, Bilbao, Spain; ⁴Nephrology, Hospital Universitario, A Coruña, Spain; ⁵Nephrology, Hospital del Mar, Barcelona, Spain; ⁶Nephrology, Hospital Puerta del Mar, Cadiz, Spain; ⁷Nephrology, Hospital General, Oviedo, Spain; ⁸Nephrology, Hospital Virgen del Rocío, Sevilla, Spain
In a longuitudinal study,we evaluated the cumulative incidence of Posttransplant limphoproliferative disorders(PTLD),its relationship with Epstein Barr Virus (EBV),classical risk factors and outcome in 21546 single…
2017 American Transplant Congress
Protective Effect of New Delivery System of Nitric Oxide Releasing Nanofiber in Rat Model of Renal Ischemia-Reperfusion Injury.
J. Kim,¹ H. Ahn,² D. Kim,¹ S. Jung,¹ E. Park,¹ T. Lee,¹ C. Ihm,¹ S. Lee,¹ J. Moon,¹ Y. Kim,¹ K. Jeong.¹
¹Nephrology, Kyung Hee University Medical Center, Seoul, Korea; ²Surgery, Kyung Hee University Medical Center, Seoul, Korea
Objective: Renal ischemia-reperfusion injury (IRI) is very important in various clinical setting including kidney transplantation. Nitric oxide (NO) is well known for having various protective…
2017 American Transplant Congress
Alemtuzumab Induction and Belatacept Maintenance in Marginal Pathology Renal Allografts.
T. Sparkes, B. Ravichandran, O. Opara, R. Ugarte, J. Bromberg, R. Barth.
University of Maryland, Baltimore
Background: The potential for improved outcomes with CNI avoidance may be important for kidneys with an increased likelihood of impaired graft function. We performed a…